Clinical Trial Update: Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial of zanubrutinib in combination with R-PolaCHP for newly diagnosed diffuse large B-cell lymphoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Transformed Follicular Lymphoma to Diffuse Large B-cell Lymphoma
• Transformed Marginal Zone Lymphoma to Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (Rituxan) (rituximab)
• Vincristine (vincristine)
• Zanubrutinib (Brukinsa) (zanubrutinib)

Snippet

Sponsor: Yazeed Sawalha | Conditions: Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Status: SUSPENDED